RAPP
Rapport Therapeutics, Inc.
33.80$
-0.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +130.4% | +186.8% | +36.8% | +5.3% | +18.7% | -6.2% | +3.3% | +1.6% | +3.5% | -14.3% | -6.6% | – | |
| – | +16.2% | +49.4% | +57.9% | +35.2% | +0.8% | +25.9% | +8.6% | +7.9% | +20.2% | +22.4% | +3.4% | – | |
| – | -14.9% | -262.4% | – | – | -59.1% | -132.3% | – | – | -2.5% | -121.2% | – | – | |
| – | +2,663.5% | -25.4% | -9.8% | -85.5% | +61.4% | +28.8% | -92.4% | +509.1% | +26.1% | -49.1% | -9.3% | – | |
| – | +151,171.2% | -46.7% | +155.5% | -50.5% | – | -34.1% | +7.4% | -351.3% | +207.0% | – | -32.5% | – | |
| – | -100.0% | – | – | – | – | – | -100.0% | – | – | – | +0.0% | – | |
| – | -100.2% | – | +150.3% | -100.9% | – | -28.6% | -1,360.0% | – | -99.9% | +70.7% | +165.7% | – | |
| – | -211.6% | – | +771.7% | -297.4% | – | -95.4% | -417.5% | – | -201.2% | – | -156.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.